{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-23-000029","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.211091+00:00","generated_at":"2026-06-08T21:42:14.750428+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vertex Q3 product revenue $2.48B (+6% YoY); raises FY2023 guidance to ~$9.85B","bullets":["Product revenue $2.48B (+6% YoY); U.S. $1.55B (+7%), ex-U.S. $929M (+6%).","FY2023 product revenue guidance raised to ~$9.85B (from $9.7-9.8B); opex guidance unchanged.","Exa-cel PDUFA for SCD Dec 8, 2023; BLA Priority Review; EU/UK reviews ongoing.","Phase 3 data for vanzacaftor triple and VX-548 acute pain expected early 2024; Phase 2 neuropathic pain data late 2023.","Cash and marketable securities $13.6B at Sep 30, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-23-000029","json":"https://secwatch.observer/filing/0000875320-23-000029.json","markdown":"https://secwatch.observer/filing/0000875320-23-000029.md","text":"https://secwatch.observer/filing/0000875320-23-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000029/0000875320-23-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000029/vrtx-20231106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:42:14.750428+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8dbb8dadc541bf719c0a6ee8eed86b0999db1f2b","claim":"VERTEX PHARMACEUTICALS INC / MA updated its full year 2023 guidance (raised).","evidence_excerpt":"Vertex today raised its full year 2023 CF product revenue guidance to approximately $9.85 billion.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000029/0000875320-23-000029-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"de127ba9bd5624e668b4c4ba6519da6848b4b55f","claim":"VERTEX PHARMACEUTICALS INC / MA reported third quarter ended September 30, 2023 results: revenue $2.48 billion. Guidance raised.","evidence_excerpt":"as shall be expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Vertex Reports Third Quarter 2023 Financial Results — Product revenue of $2.48 billion, a 6% increase compared to Q3 2022 — — Company raises full year 2023 product revenue guidance to approximately $9.85 billion — — U.S. FDA Advisory Committee meeting for exa-cel","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000029/0000875320-23-000029-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$2.48 billion"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}